Torisel (temsirolimus) / Pfizer 
Welcome,         Profile    Billing    Logout  
 366 Diseases   40 Trials   40 Trials   1659 News 


«12...4567891011121314...2223»
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Trial primary completion date:  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov) -  Mar 16, 2020   
    P3,  N=253, Active, not recruiting, 
    These observations indicate that the ALDH1A3-mTOR axis could be a novel therapeutic target to eradicate drug-tolerant gastric cancer cells. Trial primary completion date: Mar 2020 --> Jun 2020
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Journal:  Current and emerging first-line systemic therapies in metastatic clear-cell renal cell carcinoma. (Pubmed Central) -  Mar 8, 2020   
    Nivolumab/ipilimumab (dual checkpoint inhibitors) seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended...These emerging therapies include the combinations of pembrolizumab/lenvatinib, pembrolizumab/axitinib, avelumab/axitinib and atezolizumab/ bevacizu-mab and seem to introduce the mccRCC therapy in a new auspicious era. Moreover, emerging new targeted therapies and other, beyond ICIs, immunotherapies are currently underway.
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Trial completion, Metastases:  Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) -  Feb 24, 2020   
    P2,  N=31, Completed, 
    Further studies are needed to assess IL-17 and VEGF in the crevicular fluid in patients with and without periodontal disease. Active, not recruiting --> Completed
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Journal:  Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. (Pubmed Central) -  Feb 22, 2020   
    Temsirolimus not only benefits poor-risk nccRCC patients, but it is also effective in favorable or intermediate-risk group in Asians. Temsirolimus was well-tolerated with manageable adverse events.
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO) (clinicaltrials.gov) -  Feb 19, 2020   
    P2,  N=100, Active, not recruiting, 
    Temsirolimus was well-tolerated with manageable adverse events. Recruiting --> Active, not recruiting | N=60 --> 100 | Trial completion date: Feb 2020 --> Sep 2021 | Trial primary completion date: Aug 2019 --> Sep 2020
  • ||||||||||  Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
    Journal:  Local and distant recurrence of the chromophobe renal cell carcinoma. (Pubmed Central) -  Feb 14, 2020   
    The other three cases were unresectable surgicallyand received sunitinib. One patient now has a stable diseaseand the two others died.  Chromophobe renal cell carcinomashowed a greater tendency to metastasize, so requires asurveillance protocol based on the risk of recurrence.
  • ||||||||||  Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
    Enrollment change, Trial primary completion date, Combination therapy, Metastases:  Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) -  Jan 23, 2020   
    P1,  N=27, Active, not recruiting, 
    1 case exhibited a TMB burden of 9 mutations/Mb, indicating it may responde to immune therapy. N=114 --> 27 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Journal:  Identification and characterization of two novel oncogenic mTOR mutations. (Pubmed Central) -  Dec 20, 2019   
    We also demonstrated that transfection with the novel mutants conferred cells high sensitivities to the mTOR inhibitor temsirolimus. We speculate that human cancers harboring these mTOR mutations, such as ATC and melanoma, may be effectively treated with inhibitors targeting mTOR.
  • ||||||||||  Journal:  Autophagy as a molecular target for cancer treatment. (Pubmed Central) -  Dec 20, 2019   
    In this sense, we also review the shared regulatory pathways that play a role in autophagy and malignant transformation. Finally, anti-cancer therapeutic agents used as either inhibitors or inducers of autophagy have been discussed.
  • ||||||||||  Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
    Trial completion date, Trial primary completion date, Metastases:  Phase II Study of Alternating Sunitinib and Temsirolimus (clinicaltrials.gov) -  Dec 10, 2019   
    P2,  N=37, Active, not recruiting, 
    Trial completion date: Dec 2019 --> Dec 2020 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Trial primary completion date:  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (clinicaltrials.gov) -  Dec 9, 2019   
    P3,  N=253, Active, not recruiting, 
    Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial primary completion date: Dec 2019 --> Mar 2020
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal, Adverse events, HEOR, Real-world evidence:  Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. (Pubmed Central) -  Nov 22, 2019   
    In the US, 1 L TK/VEGF inhibitor uptake in recent years appears largely in line with national approvals and guidelines, with varied 2 L agent use. Although retrospective evaluation of claims data cannot assess underlying causality, insights from these real-world RCC treatment and AE patterns will be useful in informing medical and payer decisions.
  • ||||||||||  Avastin (bevacizumab) / Roche, everolimus / Generic mfg.
    Journal, HEOR:  Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. (Pubmed Central) -  Nov 19, 2019   
    Metaplastic breast cancers (MpBCs) represent <1% of all breast cancers, demonstrate mesenchymal differentiation, and are typically resistant to chemotherapy. Patients with advanced MpBC treated with an mTOR-based systemic therapy regimen had better long-term outcomes compared with patients with nonmetaplastic triple-negative breast cancer treated with the same regimen, suggesting that metaplastic histology may predict benefit from agents targeting the PI3K/Akt/mTOR pathway.
  • ||||||||||  Torisel (temsirolimus) / Pfizer
    Clinical, P1 data, Journal:  Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218. (Pubmed Central) -  Nov 14, 2019   
    Patients with advanced MpBC treated with an mTOR-based systemic therapy regimen had better long-term outcomes compared with patients with nonmetaplastic triple-negative breast cancer treated with the same regimen, suggesting that metaplastic histology may predict benefit from agents targeting the PI3K/Akt/mTOR pathway. The combination of weekly temsirolimus (15 mg/m ) and vinblastine (4 mg/m ) exceeds the maximum tolerated dose in children, with frequent oral mucositis and hematologic toxicity.
  • ||||||||||  Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_5697;    
    Results Pairwise combinations screen of venetoclax with candidate small molecule inhibitors and chemotherapeutic drugs on primary T-PLL cells revealed synergistic action of venetoclax with ibrutinib, idelalisib, and 5-azacytidine, and to lower extents Olaparib, Temsirolimus, Ruxolitinib and Belinostat whereas cisplatin antagonized the effect of venetoclax across all patient samples tested (Fig 1b)...Two patients suffering from r/r T-PLL after failing at least two treatment lines including alemtuzumab were treated with the combination of venetoclax and ibrutinib resulting in significant clinical responses with substantial drops in leukocytosis and LDH as well as substantial clinical improvement (Fig 2a, b)...Mechanistically, ibrutinib dephosphorylated ITK in T-PLL cells and, furthermore, enhanced BCL2 dependency, both, in-vivo and in-vitro. Patients treated with the combination venetoclax and ibrutinib experienced profound clinical responses which needs further evaluation in an prospective clinical study on a larger cohort of r/r T-PLL patients.